drugset / Trial / NCT06917092
QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer
NaSingle-groupOpen-labelPrevention
Summary
This is a prospective, single-arm, multicenter Phase II study evaluating the efficacy and safety of QL1706 combined with chemotherapy in patients with advanced recurrent or metastatic endometrial cancer who progressed after prior anti-PD-1/L1 therapy.
Timeline
- Start
- 2025-05-01
- Primary completion
- 2027-04-30
- Completion
- 2030-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | QL1706 | Monoclonal antibody | 5 mg/kg | Intravenous |